# Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Source: https://onco.cc/trials/nct04976634/  
OnCo record `nct04976634` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab, Belzutifan and Lenvatinib in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) is a phase 2 interventional study registered as NCT04976634 by Merck Sharp & Dohme LLC, with 730 participants enrolled, started 2021-08-18 and due to reach its primary completion in 2027-03-22. Interventions recorded: Pembrolizumab, Belzutifan and Lenvatinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04976634
- Phase: 2
- Setting: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 730

## Sources

- ClinicalTrials.gov NCT04976634: https://clinicaltrials.gov/study/NCT04976634

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Belzutifan](https://onco.cc/drugs/belzutifan/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04976634.json